These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33931924)

  • 1. Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.
    Du W; Gao A; Herman JG; Wang L; Zhang L; Jiao S; Guo M
    Cancer Sci; 2021 Jul; 112(7):2870-2883. PubMed ID: 33931924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of IGFBPL1 promotes esophageal cancer growth by activating PI3K-AKT signaling.
    Liu Y; Zhang M; He T; Yang W; Wang L; Zhang L; Guo M
    Clin Epigenetics; 2020 Feb; 12(1):22. PubMed ID: 32041673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cucurbitacin E inhibits esophageal carcinoma cell proliferation, migration, and invasion by suppressing Rac1 expression through PI3K/AKT/mTOR pathway.
    Zhang L; Liang H; Xin Y
    Anticancer Drugs; 2020 Sep; 31(8):847-855. PubMed ID: 32568828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
    Zhu DS; Dong JY; Xu YY; Zhang XT; Fu SB; Liu W
    Med Sci Monit; 2020 Aug; 26():e927106. PubMed ID: 32804918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
    Wang G; Sun J; Zhao H; Li H
    Med Sci Monit; 2018 Oct; 24():7689-7696. PubMed ID: 30368517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oridonin-induced mitochondria-dependent apoptosis in esophageal cancer cells by inhibiting PI3K/AKT/mTOR and Ras/Raf pathways.
    Jiang JH; Pi J; Jin H; Cai JY
    J Cell Biochem; 2019 Mar; 120(3):3736-3746. PubMed ID: 30229997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGIF1 plays a carcinogenic role in esophageal squamous cell carcinoma through the Wnt/β‑catenin and Akt/mTOR signaling pathways.
    Kong L; Yu Y; Guan H; Jiang L; Sun F; Li X; Huang W; Li B
    Int J Mol Med; 2021 May; 47(5):. PubMed ID: 33693954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis.
    Ji YM; Zhou XF; Zhang J; Zheng X; Li SB; Wei ZQ; Liu T; Cheng DL; Liu P; Song K; Tan T; Zhu H; Guo JL
    Oncotarget; 2016 Mar; 7(12):14188-98. PubMed ID: 26893358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
    Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma.
    Yang Z; Liu H; Song Y; Gao N; Gao P; Hui Y; Li Y; Fan T
    Int J Mol Med; 2024 Sep; 54(3):. PubMed ID: 38994756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma.
    Zhang X; Zou N; Deng W; Song C; Yan K; Shen W; Zhu S
    Mol Biol Rep; 2022 Dec; 49(12):11933-11945. PubMed ID: 36260180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression.
    Wang L; Zhang Z; Yu X; Li Q; Wang Q; Chang A; Huang X; Han X; Song Y; Hu J; Pang L; Hou J; Li F
    Cancer Lett; 2020 Jan; 468():14-26. PubMed ID: 31600529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway.
    Guanen Q; Junjie S; Baolin W; Chaoyang W; Yajuan Y; Jing L; Junpeng L; Gaili N; Zhongping W; Jun W
    Biomed Pharmacother; 2018 Sep; 105():350-361. PubMed ID: 29864623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of sine oculis homeobox homolog 3 is associated with proliferation, invasion, migration, as well as poor prognosis of esophageal cancer.
    Du J
    Anticancer Drugs; 2019 Jul; 30(6):596-603. PubMed ID: 30672777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling.
    Cao B; Yang W; Jin Y; Zhang M; He T; Zhan Q; Herman JG; Zhong G; Guo M
    J Thorac Oncol; 2016 Nov; 11(11):1912-1926. PubMed ID: 27374455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
    Gen Y; Yasui K; Nishikawa T; Yoshikawa T
    Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A GRN Autocrine-Dependent FAM135B/AKT/mTOR Feedforward Loop Promotes Esophageal Squamous Cell Carcinoma Progression.
    Dong D; Zhang W; Xiao W; Wu Q; Cao Y; Gao X; Huang L; Wang Y; Chen J; Wang W; Zhan Q
    Cancer Res; 2021 Feb; 81(4):910-922. PubMed ID: 33323378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.
    Peng Y; Zhou Y; Cheng L; Hu D; Zhou X; Wang Z; Xie C; Zhou F
    Biochem Biophys Res Commun; 2015 Sep; 465(1):137-44. PubMed ID: 26235881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.